- Home »
- Quarterly Results »
- AstraZeneca Pharma India Q1 Results, Net Loss of ₹110.5 Million and Total Income of ₹3,958.7 Million
AstraZeneca Pharma India Q1 Results, Net Loss of ₹110.5 Million and Total Income of ₹3,958.7 Million
AstraZeneca Pharma India Q1 Results report a 1.02% QoQ increase in total income to ₹3,958.7 million, but AstraZeneca Pharma India Q1 Results also show an operating profit of ₹-23.40 crore with a -6.04% operating margin and a net loss of ₹110.5 million.
by P Nandhini
Updated Sep 19, 2024
Table of Content
AstraZeneca Pharma India Q1 Results: AstraZeneca Pharma India declared its Q1 results for the financial year 2024-2025 on August 8, 2024, showing a 1.02% quarter-on-quarter (QoQ) increase in total expenses. Total expenses for the quarter ending June 2024 rose to ₹3,534.7 million, compared to ₹3,375.0 million in the March 2024 quarter.
Despite the increase in expenses, the company's revenue from operations showed only a 1.12% QoQ increase, reaching ₹3,875.2 million. This rise in total expenses was driven primarily by a significant 220.6% QoQ increase in purchases of stock-in-trade, which surged to ₹2,403.3 million from ₹749.8 million in the previous quarter.
Employee benefit expenses also grew by 5.1% QoQ, contributing to the overall rise in costs. The increase in expenses outpaced the growth in revenue, leading to a net loss of ₹110.5 million for the quarter, compared to a profit of ₹396.8 million in Q4 of the previous fiscal year.
For More Q1 results check our Twitter Page
AstraZeneca Pharma India Q1 Results 2024 - 2025
AstraZeneca Pharma India announced its Q1 results for the financial year 2024-2025 on August 8, 2024. The results show a slight increase in revenue but a significant rise in expenses, leading to a net loss for the quarter. Below is a summary of the key financial metrics from Q1 compared to the previous quarter:
| Particulars | Q1 FY 2024-2025 (June 2024) | Q4 FY 2023-2024 (March 2024) | QoQ Change |
|---|---|---|---|
| Revenue from operations (₹ million) | 3,875.2 | 3,832.0 | +1.12% |
| Other income (₹ million) | 83.5 | 86.6 | -3.58% |
| Total income (₹ million) | 3,958.7 | 3,918.6 | +1.02% |
| Total expenses (₹ million) | 3,534.7 | 3,375.0 | +4.73% |
| Cost of materials consumed (₹ million) | 458.5 | 336.2 | +36.4% |
| Purchases of stock-in-trade (₹ million) | 2,403.3 | 749.8 | +220.6% |
| Employee benefit expenses (₹ million) | 609.6 | 579.8 | +5.1% |
| Depreciation expense (₹ million) | 39.1 | 37.6 | +4.0% |
| Profit/(Loss) before tax (₹ million) | (151.6) | 643.6 | -123.6% |
| Exceptional items (₹ million) | (575.6) | – | N/A |
| Earnings per share (₹) | (4.72) | 15.79 | -130% |
| Total comprehensive income/(loss) (₹ million) | (110.5) | 396.8 | -127.8% |
Source: Click Here
AstraZeneca Pharma India Current Market Overview
Here is a table summarizing the current market overview of AstraZeneca Pharma India:
| Particulars | Details |
|---|---|
| Current Price | ₹6,727 |
| Change | +0.35% |
| Market Capitalization | ₹16,817 crore |
| 52-Week High | ₹7,572 |
| 52-Week Low | ₹4,050 |
| Stock P/E | 128 |
| Book Value | ₹285 |
| Dividend Yield | 0.36% |
| Return on Capital Employed (ROCE) | 31.1% |
| Return on Equity (ROE) | 22.9% |
| Face Value | ₹2.00 |
Quarterly Results
Here is a summary of AstraZeneca Pharma India's quarterly results for the recent periods. The table below includes key financial metrics such as sales, expenses, operating profit, and net profit for December 2023, March 2024, and June 2024:
| Metric | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|
| Sales (₹ Cr) | 306 | 383 | 388 |
| Expenses (₹ Cr) | 291 | 334 | 349 |
| Operating Profit (₹ Cr) | 15 | 49 | 38 |
| Operating Profit Margin (OPM %) | 5% | 13% | 10% |
| Other Income (₹ Cr) | 10 | 9 | -49 |
| Profit Before Tax (₹ Cr) | 20 | 54 | -15 |
| Net Profit (₹ Cr) | 16 | 39 | -12 |
| Earnings Per Share (EPS ₹) | 6.32 | 15.79 | -4.72 |
AstraZeneca Pharma India
AstraZeneca Pharma India, established in 1979, is a leading pharmaceutical company based in Bengaluru, Karnataka. It is a subsidiary of AstraZeneca Plc, UK, and focuses on manufacturing, sales, and marketing of medicines in India.
The company is science-driven and committed to improving healthcare by developing innovative treatments for various medical conditions. AstraZeneca Pharma India is known for its work in areas such as oncology, cardiovascular health, and respiratory diseases, aiming to make a positive impact on patients' lives and healthcare across the country.
Check our website for more Q1 results.
Astrazeneca Pharma India Q1 Results - FAQs
1. What is AstraZeneca Pharma India's total income for Q1 FY 2024-2025?
AstraZeneca Pharma India's total income for Q1 FY 2024-2025 is ₹3,958.7 million.
2. How much did AstraZeneca Pharma India’s revenue from operations increase in Q1 FY 2024-2025?
AstraZeneca Pharma India's revenue from operations increased by 1.12% in Q1 FY 2024-2025.
3. What was AstraZeneca Pharma India’s total expenses for the quarter ending June 2024?
AstraZeneca Pharma India’s total expenses for the quarter ending June 2024 were ₹3,534.7 million.
4. How did AstraZeneca Pharma India’s expenses change from Q4 FY 2023-2024 to Q1 FY 2024-2025?
AstraZeneca Pharma India’s expenses increased by 4.73% from Q4 FY 2023-2024 to Q1 FY 2024-2025.
5. What was the net loss reported by AstraZeneca Pharma India for Q1 FY 2024-2025?
AstraZeneca Pharma India reported a net loss of ₹110.5 million for Q1 FY 2024-2025.
6. How did AstraZeneca Pharma India’s earnings per share (EPS) change in Q1 FY 2024-2025?
AstraZeneca Pharma India’s earnings per share (EPS) decreased to ₹-4.72 in Q1 FY 2024-2025.
7. What was AstraZeneca Pharma India’s profit before tax for Q1 FY 2024-2025?
AstraZeneca Pharma India’s profit before tax for Q1 FY 2024-2025 was ₹-151.6 million.
8. What was the operating profit margin for AstraZeneca Pharma India in Q1 FY 2024-2025?
AstraZeneca Pharma India’s operating profit margin was -6.04% in Q1 FY 2024-2025.
9. What is the total comprehensive income for AstraZeneca Pharma India in Q1 FY 2024-2025?
AstraZeneca Pharma India’s total comprehensive income for Q1 FY 2024-2025 is ₹-110.5 million.
10. What is AstraZeneca Pharma India’s total income in the previous quarter?
AstraZeneca Pharma India’s total income in the previous quarter (Q4 FY 2023-2024) was ₹3,918.6 million.